Amgen entered an agreement to acquire Teneobio, a privately held, clinical stage biotechnology company developing a new class of biologics called Human Heavy-Chain Antibodies, for a $900 million upfront, and future contingent milestones, potentially worth up to an additional $1.6 billion.   The acquisition includes Teneobio’s bispecific and multispecific antibody technologies, which will enable significant acceleration and efficiency in the discovery and development of new molecules tha...